MedTrace Logo

Lidocaine Patch 1.8% for Moderate to Severe Pain From Carpal Tunnel Syndrome

NCT04245371 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2023-06-08

No results posted yet for this study

Summary

The primary objective is to determine the efficacy of Lidocaine Patch 1.8% in reducing the severity of symptoms in participants with moderate-to-severe pain from Carpal Tunnel Syndrome.

Conditions

  • Carpal Tunnel Syndrome

Interventions

DRUG

Lidocaine 1.8%

Topical Patch

DRUG

Placebo

Matching Placebo Patch

Sponsors & Collaborators

  • Scilex Ltd.

    collaborator INDUSTRY

  • John Papakonstantinou, MD

    lead OTHER

Principal Investigators

  • John Papakonstantinou, MD · Michigan Orthopaedic & Spine Surgeons

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-02-24
Primary Completion
2023-05-07
Completion
2023-05-07
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04245371 on ClinicalTrials.gov